Captrust Financial Advisors Novavax Inc Transaction History

Captrust Financial Advisors

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 23, 2022	SELL	$36.28 - $75.29 $9,650 - $20,027	-266 Reduced 3.82%	6,703 $345,000
Q2 2022 Aug 16, 2022	BUY	$36.28 - $75.29 $120,195 - $249,435	3,313 Added 90.62%	6,969 $358,000
Q1 2022 May 16, 2022	SELL	$69.73 - $142.9 $3,068 - $6,287	-44 Reduced 1.19%	3,656 $269,000
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $152,456 - $246,960	1,133 Added 44.14%	3,700 $529,000
Q3 2021 Nov 16, 2021	BUY	$177.8 - $270.58 $345,287 - $525,466	1,942 Added 310.72%	2,567 $532,000
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $1,936 - $4,122	16 Added 2.63%	625 $133,000
Q1 2021 May 17, 2021	BUY	$112.98 - $319.93 $45,079 - $127,652	399 Added 190.0%	609 $110,000
Q4 2020 Feb 16, 2021	BUY	$78.74 - $139.5 $2,125 - $3,766	27 Added 14.75%	210 $23,000
Q3 2020 Nov 17, 2020	SELL	$79.44 - $178.51 $2,939 - $6,604	-37 Reduced 16.82%	183 $19,000
Q2 2020 Aug 14, 2020	BUY	$13.86 - $83.61 $3,049 - $18,394	220 New	220 $18,000

287

94.6M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $660M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.